Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

X

William Newton

07 Jul 2021

Comment

LoA Update: Akari’s Phase III paroxysmal nocturnal hemoglobinuria asset has six-point fall in regulatory approval chances after trial termination

07 Jul 2021

01 Jul 2021

Comment

LoA Update: India Globalization Capital’s Alzheimer’s disease cannabinoid-based treatment sees 15-point boost in chances to advance to next stage after Phase I completion

01 Jul 2021

30 Jun 2021

Comment

LoA Update: Brii Biosciences/VBI Vaccines HBV asset BRII-179’s shot to transition to next development stage scale up by 11 points after Phase Ib/IIa results

30 Jun 2021

28 Jun 2021

Comment

Post-ASCO News Alert: AVEO Pharmaceuticals’ mAb ficlatuzumab has experts mixed on proposed Phase III’s earlier-line patient population compared to Phase II in head and neck cancer

28 Jun 2021

24 Jun 2021

Comment

Drug development for long Covid-19 in children warrants unique focus on how mechanisms, prevalence differ from adults

24 Jun 2021

18 Jun 2021

Comment

LoA Update: Imara’s IMR-687 for sickle cell disease, beta thalassaemia sees surge in chances to transition to next clinical stage after Phase IIa data update

18 Jun 2021

18 Jun 2021

Comment

LoA Update: Merck’s chikungunya fever vaccine trial sees 11-point spike in chances to transition to next stage after Phase II status update

18 Jun 2021

17 Jun 2021

Comment

LoA Update: Inversago’s Prader-Willi Syndrome trial sees seven-point spike in chances to transition to next stage after Phase I status update

17 Jun 2021

17 Jun 2021

Comment

LoA Update: Glycotope’s Phase Ib solid tumour trial sees five-point drop in chances to transition to next development stage after ASCO data reveal

17 Jun 2021

11 Jun 2021

Comment

LoA Update: GSK’s Zejula sees boost in chances to transition to next development stage in BAP1-mutated and DDR-deficient tumours

11 Jun 2021